Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Joshua F. Zeidner; Judith E. Karp

doi:10.1016/j.leukres.2015.10.010

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Joshua F. Zeidner, Judith E. Karp

University Administration

Research output: Contribution to journal › Review article › peer-review

Abstract

There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.

Original language	English (US)
Pages (from-to)	1312-1318
Number of pages	7
Journal	Leukemia Research
Volume	39
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2015.10.010
State	Published - Sep 2 2015

Keywords

Acute myeloid leukemia
Alvocidib
CDK inhibitors
Cyclin dependent kinase
FLAM
Flavopiridol

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2015.10.010

Cite this

@article{a3a13288fdd247ceaefebf9d7f381e2f,

title = "Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia",

abstract = "There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.",

keywords = "Acute myeloid leukemia, Alvocidib, CDK inhibitors, Cyclin dependent kinase, FLAM, Flavopiridol",

author = "Zeidner, {Joshua F.} and Karp, {Judith E.}",

year = "2015",

month = sep,

day = "2",

doi = "10.1016/j.leukres.2015.10.010",

language = "English (US)",

volume = "39",

pages = "1312--1318",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

AU - Zeidner, Joshua F.

AU - Karp, Judith E.

PY - 2015/9/2

Y1 - 2015/9/2

N2 - There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.

AB - There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.

KW - Acute myeloid leukemia

KW - Alvocidib

KW - CDK inhibitors

KW - Cyclin dependent kinase

KW - FLAM

KW - Flavopiridol

UR - http://www.scopus.com/inward/record.url?scp=84951310166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951310166&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2015.10.010

DO - 10.1016/j.leukres.2015.10.010

M3 - Review article

C2 - 26521988

AN - SCOPUS:84951310166

VL - 39

SP - 1312

EP - 1318

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this